When diagnosing the disease, mutation site genotypes of genes such as isocitrate dehydrogenase (IDH), tumor protein p53(TP53), and alpha thalassemia/mental retardation syndrome X linked (ATRX) and 1p/19q codeletion should be evaluated. This evidence concerns the gene TP53 and alpha thalassemia spectrum.